Autoantibody testing positive (n=388) | Autoantibody testing negative (n=1168) | P value | |
Sex (column % (row %)) | |||
Male | 43.8% (20.9%) | 55.1% (79.1%) | <0.001 |
Female | 56.2% (29.3%) | 45.0% (70.7%) | |
Age (years) | 51.5±10.8 | 52.3±10.5 | 0.21 |
BMI (n=208/730) | 28.7±7.5 | 28.3±6.7 | 0.49 |
History of tobacco use (n=194/675) | 45.4% | 51.9% | 0.11 |
History of alcohol use (n=147/531) | 23.1% | 27.9% | 0.25 |
Race (column % (row %)) | |||
White | 54.3% (22.3%) | 61.0% (77.8%) | 0.11 |
Asian | 14.2% (27.1%) | 12.2% (72.9%) | |
Black | 10.3% (31.3%) | 7.3% (68.8%) | |
Hispanic Ethnicity | 21.2% (26.0%) | 19.5% (74.0%) | |
Comorbidities | |||
≥2 Comorbidities | 24.2% | 28.0% | 0.15 |
Hypertension | 38.9% | 39.8% | 0.76 |
Diabetes mellitus | 21.4% | 21.9% | 0.83 |
Coronary artery disease | 10.3% | 12.7% | 0.22 |
Chronic obstructive pulmonary disease | 3.4% | 4.5% | 0.32 |
Chronic kidney disease | 11.9% | 14.7% | 0.16 |
Extrahepatic manifestations | |||
Any extrahepatic manifestation | 42.8% | 45.0% | 0.44 |
Mixed cryoglobulinaemia | 2.3% | 1.9% | 0.59 |
Depression | 21.4% | 24.7% | 0.19 |
Sjögren’s syndrome | 0.8% | 0.3% | 0.22 |
Rheumatoid arthritis | 3.4% | 3.0% | 0.73 |
Lymphoma | 1.0% | 0.4% | 0.18 |
Treatment status | |||
History of HCV antiviral therapy prior to presentation (n=284/679) | 32.0% | 36.1% | 0.23 |
Received antiviral therapy after presentation | 28.6% | 30.6% | 0.47 |
Received antiviral therapy at any time | 43.3% (168) | 42.3% (494) | 0.73 |
SVR achieved (n=149/452) | 37.2% | 47.1% | 0.031 |
IFN-based therapy | 29.0% | 42.7% | 0.012 |
DAA therapy | 67.6% | 71.4% | 0.65 |
HCV genotype (n=281/773) | |||
1 Untyped | 15.7% | 11.3% | 0.48 |
1a | 34.5% | 36.4% | |
1b | 21.0% | 21.9% | |
2 | 13.9% | 14.6% | |
3 | 12.5% | 12.2% | |
4 | 0.7% | 1.9% | |
6 | 1.8% | 1.8% | |
Baseline disease state and severity | |||
Baseline cirrhosis | 41.5% | 44.3% | 0.34 |
Baseline history of decompensation | 28.4% | 29.7% | 0.61 |
Baseline HCC | 4.1% | 4.9% | 0.54 |
Log10 HCV RNA (IU/mL) (n=263/777) | 4.58±0.02 | 4.59±0.02 | 0.0016 |
Baseline MELD in patients with baseline cirrhosis | 16.3±7.9 | 16.6±8.6 | 0.83 |
Baseline CTP (n = 113 /408) | |||
A | 36.3% | 40.2% | 0.24 |
B | 35.4% | 39.0% | |
C | 28.3% | 20.8% |
BMI, body mass index; CTP, Child-Turcotte-Pugh; DAA, direct acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; MELD, Model for End-Stage Liver Disease; SVR, sustained virological response.